Ayala Pharmaceuticals (ADXS) Competitors $0.12 0.00 (0.00%) As of 07/8/2025 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. BFRI, KTTA, FRTX, ENSC, ALBT, APM, ATNF, CNSP, THAR, and MYNZShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Pasithea Therapeutics (KTTA), Fresh Tracks Therapeutics (FRTX), Ensysce Biosciences (ENSC), Avalon GloboCare (ALBT), Aptorum Group (APM), 180 Life Sciences (ATNF), CNS Pharmaceuticals (CNSP), Tharimmune (THAR), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Biofrontera Pasithea Therapeutics Fresh Tracks Therapeutics Ensysce Biosciences Avalon GloboCare Aptorum Group 180 Life Sciences CNS Pharmaceuticals Tharimmune Mainz Biomed Ayala Pharmaceuticals (NASDAQ:ADXS) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media favor ADXS or BFRI? In the previous week, Biofrontera had 6 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 0 mentions for Ayala Pharmaceuticals. Biofrontera's average media sentiment score of 0.52 beat Ayala Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media. Company Overall Sentiment Ayala Pharmaceuticals Neutral Biofrontera Positive Which has better valuation & earnings, ADXS or BFRI? Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M1.58-$48.07M-$7.98-0.02Biofrontera$37.32M0.18-$17.76M-$2.26-0.32 Is ADXS or BFRI more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -30.33%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Biofrontera -30.33%-305.13%-82.67% Which has more risk and volatility, ADXS or BFRI? Ayala Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Do institutionals and insiders believe in ADXS or BFRI? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer ADXS or BFRI? Biofrontera has a consensus target price of $2.75, indicating a potential upside of 277.23%. Given Biofrontera's stronger consensus rating and higher probable upside, analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiofrontera beats Ayala Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.13M$780.02M$5.47B$8.95BDividend YieldN/A4.84%5.25%4.06%P/E Ratio-0.021.0927.0020.10Price / Sales1.58230.52435.75120.24Price / CashN/A23.4436.8257.86Price / Book-0.066.137.985.56Net Income-$48.07M-$27.85M$3.16B$248.40M7 Day PerformanceN/A0.67%2.41%4.67%1 Month PerformanceN/A8.48%2.19%6.64%1 Year Performance-19.80%6.72%33.82%21.31% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.12flatN/A-7.5%$5.13M$3.24M-0.0220BFRIBiofrontera2.1482 of 5 stars$0.71+18.3%$2.75+286.5%-15.3%$5.68M$37.32M-0.3170KTTAPasithea Therapeutics0.9751 of 5 stars$0.72-5.0%N/A-86.0%$5.65MN/A-0.073Positive NewsFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+1.6%$5.59M$10.06M-0.6620ENSCEnsysce Biosciences0.0799 of 5 stars$2.23-0.4%N/A-68.5%$5.31M$5.21M-0.3410ALBTAvalon GloboCare1.6833 of 5 stars$2.78flatN/A-65.9%$5.27M$1.33M-0.145Positive NewsAPMAptorum Group0.5048 of 5 stars$0.91-6.3%N/A-77.2%$5.19M$430K0.0030Gap UpATNF180 Life Sciences0.5729 of 5 stars$0.93+11.8%N/A-50.7%$5.04MN/A0.007CNSPCNS Pharmaceuticals1.6728 of 5 stars$0.83-6.1%$25.00+2,930.3%-98.4%$4.80MN/A0.005THARTharimmune2.7733 of 5 stars$1.94+7.6%$17.00+776.2%-48.8%$4.80MN/A-0.252Positive NewsMYNZMainz Biomed3.0701 of 5 stars$1.41+2.2%$14.00+892.9%-92.4%$4.75M$890K-0.0230Gap Up Related Companies and Tools Related Companies Biofrontera Alternatives Pasithea Therapeutics Alternatives Fresh Tracks Therapeutics Alternatives Ensysce Biosciences Alternatives Avalon GloboCare Alternatives Aptorum Group Alternatives 180 Life Sciences Alternatives CNS Pharmaceuticals Alternatives Tharimmune Alternatives Mainz Biomed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
